NASDAQ:OABI OmniAb (OABI) Stock Price, News & Analysis → AI healthcare stock poised for 36,996% growth? (From Behind the Markets) (Ad) Free OABI Stock Alerts $5.42 +0.03 (+0.56%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.37▼$5.5050-Day Range$5.13▼$6.3352-Week Range$3.14▼$6.72Volume410,830 shsAverage Volume444,741 shsMarket Capitalization$630.02 millionP/E RatioN/ADividend YieldN/APrice Target$9.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get OmniAb alerts: Email Address OmniAb MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside69.7% Upside$9.20 Price TargetShort InterestHealthy5.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 32 Articles This WeekInsider TradingAcquiring Shares$1.17 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.58) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.98 out of 5 starsMedical Sector405th out of 938 stocksCommercial Physical Research Industry6th out of 10 stocks 3.5 Analyst's Opinion Consensus RatingOmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.20, OmniAb has a forecasted upside of 69.7% from its current price of $5.42.Amount of Analyst CoverageOmniAb has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.05% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in OmniAb has recently decreased by 6.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOmniAb does not currently pay a dividend.Dividend GrowthOmniAb does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OABI. Previous Next 2.6 News and Social Media Coverage News SentimentOmniAb has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 32 news articles for OmniAb this week, compared to 2 articles on an average week.MarketBeat Follows10 people have added OmniAb to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OmniAb insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,167,750.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of OmniAb is held by insiders.Percentage Held by Institutions72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OmniAb are expected to grow in the coming year, from ($0.58) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OmniAb is -10.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OmniAb is -10.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmniAb has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsAI healthcare stock poised for 36,996% growth?Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...Get the name of the stock here... About OmniAb Stock (NASDAQ:OABI)OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.Read More OABI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OABI Stock News HeadlinesMarch 26, 2024 | insidertrades.comMatthew W. Foehr Acquires 225,000 Shares of OmniAb, Inc. (NASDAQ:OABI) StockMarch 28, 2024 | msn.comOver $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are BuyingMarch 28, 2024 | Behind the Markets (Ad)AI healthcare stock poised for 36,996% growth?Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...March 27, 2024 | americanbankingnews.comOmniAb's (OABI) "Buy" Rating Reaffirmed at Truist FinancialMarch 26, 2024 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Analysts Are More Bearish Than They Used To BeMarch 26, 2024 | americanbankingnews.comOmniAb (NASDAQ:OABI) Trading 7.6% Higher Following Insider Buying ActivityMarch 25, 2024 | finance.yahoo.comOmniAb Inc (OABI) President and CEO Matthew Foehr Acquires 225,000 SharesMarch 25, 2024 | americanbankingnews.comHC Wainwright Analysts Reduce Earnings Estimates for OmniAb, Inc. (NASDAQ:OABI)March 28, 2024 | Behind the Markets (Ad)AI healthcare stock poised for 36,996% growth?Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...March 24, 2024 | americanbankingnews.comOmniAb (NASDAQ:OABI) Sees Unusually-High Trading VolumeMarch 23, 2024 | americanbankingnews.comOmniAb's (OABI) "Buy" Rating Reaffirmed at BenchmarkMarch 23, 2024 | americanbankingnews.comRoyal Bank of Canada Reiterates "Outperform" Rating for OmniAb (NASDAQ:OABI)March 23, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for OmniAb (NASDAQ:OABI)March 23, 2024 | americanbankingnews.comAnalysts Set Expectations for OmniAb, Inc.'s FY2025 Earnings (NASDAQ:OABI)March 22, 2024 | markets.businessinsider.comBenchmark Co. Reaffirms Their Buy Rating on OmniAb (OABI)March 21, 2024 | markets.businessinsider.comOmniAb’s Market Potential and Financial Stability Affirm Buy RatingMarch 21, 2024 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comOmniAb’s Strategic Growth and Resilience Reinforce Buy Rating Amidst Q4 Revenue ShortfallMarch 20, 2024 | msn.comOABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023March 20, 2024 | finance.yahoo.comOmniAb Inc (OABI) Reports Decline in Annual Revenue and Net Loss for Q4 and Full Year 2023March 20, 2024 | seekingalpha.comOmniAb, Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 20, 2024 | benzinga.comRecap: OmniAb Q4 EarningsMarch 20, 2024 | finance.yahoo.comOmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 18, 2024 | americanbankingnews.comOmniAb (OABI) Set to Announce Earnings on WednesdayFebruary 28, 2024 | realmoney.thestreet.com2 Speculative Small-Cap Biotech Stocks You Should Know AboutFebruary 26, 2024 | businesswire.comOmniAb to Report Fourth Quarter 2023 Financial Results on March 20February 26, 2024 | businesswire.comOmniAb to Report Fourth Quarter 2023 Financial Results on March 20See More Headlines Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:OABI CUSIPN/A CIK1846253 Webwww.omniab.com Phone510-250-7800FaxN/AEmployees95Year FoundedN/APrice Target and Rating Average Stock Price Target$9.20 High Stock Price Target$11.00 Low Stock Price Target$7.00 Potential Upside/Downside+67.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,620,000.00 Net Margins-148.16% Pretax Margin-188.39% Return on Equity-15.41% Return on Assets-12.77% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio4.26 Sales & Book Value Annual Sales$34.16 million Price / Sales18.65 Cash FlowN/A Price / Cash FlowN/A Book Value$2.96 per share Price / Book1.85Miscellaneous Outstanding Shares116,240,000Free Float108,101,000Market Cap$637.00 million OptionableOptionable Beta-0.16 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Matthew W. Foehr (Age 51)President, CEO & Director Comp: $967.72kMr. Kurt A. Gustafson (Age 56)Executive VP of Finance & CFO Comp: $558.48kMr. Charles S. Berkman J.D. (Age 55)Chief Legal Officer & Secretary Comp: $734.33kMs. Cia McCaffreyVice President of People & TalentDr. Bill Harriman Ph.D.Senior Vice President of Antibody DiscoveryMs. Marie-Cecile van de Lavoir D.V.M.Ph.D., Senior Vice President of Technical Operations & GeneticsDr. Christel Iffland Ph.D.Senior Vice President of Antibody TechnologiesDr. Douglas S. Krafte Ph.D. (Age 66)Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head Ms. Donna Ventura CPASenior Vice President of Corporate ControllerMore ExecutivesKey CompetitorsAbsciNASDAQ:ABSIMaxCyteNASDAQ:MXCTCorsair PartneringNYSE:CORSDTRT Health AcquisitionNASDAQ:DTRTInotivNASDAQ:NOTVView All CompetitorsInsiders & InstitutionsMatthew W FoehrBought 225,000 shares on 3/22/2024Total: $1.17 M ($5.19/share)Vanguard Group Inc.Bought 155,464 shares on 3/11/2024Ownership: 4.862%Goldman Sachs Group Inc.Bought 18,542 shares on 3/1/2024Ownership: 0.163%Virtu Financial LLCBought 16,232 shares on 2/26/2024Ownership: 0.014%Price T Rowe Associates Inc. MDBought 2,238 shares on 2/16/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions OABI Stock Analysis - Frequently Asked Questions Should I buy or sell OmniAb stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OABI shares. View OABI analyst ratings or view top-rated stocks. What is OmniAb's stock price target for 2024? 5 analysts have issued 1-year target prices for OmniAb's shares. Their OABI share price targets range from $7.00 to $11.00. On average, they anticipate the company's share price to reach $9.20 in the next year. This suggests a possible upside of 69.7% from the stock's current price. View analysts price targets for OABI or view top-rated stocks among Wall Street analysts. How have OABI shares performed in 2024? OmniAb's stock was trading at $6.17 at the start of the year. Since then, OABI shares have decreased by 12.2% and is now trading at $5.42. View the best growth stocks for 2024 here. When is OmniAb's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our OABI earnings forecast. Who are OmniAb's major shareholders? OmniAb's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.86%), Vanguard Group Inc. (4.86%), Private Management Group Inc. (2.27%), Dimensional Fund Advisors LP (2.26%), Villere ST Denis J & Co. LLC (1.85%) and Orchard Capital Management LLC (1.17%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr. View institutional ownership trends. How do I buy shares of OmniAb? Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OABI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OmniAb, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.